Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?
• Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
• Age ≥ 18 years and ≤ 90 years.
• Adequate liver function, defined as:
‣ Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
⁃ Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
⁃ Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN
• Adequate renal functions, defined as:
• • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \> 50ml/min.
• ECOG performance status ≤ 3
• Women of reproductive potential should have a serum pregnancy test or negative urine.
• Prior signature of the informed consent.